Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) ended Thursday session in red amid volatile trading. The shares closed down -0.22 points or -0.17% at $127.52 with 1.92 million shares getting traded. Post opening the session at $128.93, the shares hit an intraday low of $127.28 and an intraday high of $131.03 and the price vacillated in this range throughout the day. The company has a market cap of $27.80 billion and the numbers of outstanding shares have been calculated to be 231.40 million shares.
Alexion Pharmaceuticals, Inc. (ALXN) recently declared the initiation of two Phase 3 trials of ALXN1210, a highly innovative, longer-acting anti-C5 antibody that inhibits terminal complement. The first trial is a Phase 3 open-label, multinational, active-controlled study of ALXN1210 contrast to eculizumab (Soliris®) in complement inhibitor treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH). Alexion has also accelerated the initiation of a registration trial of ALXN1210 in patients with atypical hemolytic uremic syndrome (aHUS). This second trial is a Phase 3, open-label, single arm, multinational trial to evaluate the safety and efficacy of ALXN1210 in complement inhibitor treatment-naïve adolescent and adult patients with aHUS. Both studies will evaluate ALXN1210 administered intravenously every eight weeks. Alexion anticipates to begin enrolling patients into these trials later this year, and plans to initiate a Phase 3 trial of ALXN1210 in pediatric patients with aHUS in 2017.
Shares of StemCells Inc (NASDAQ:STEM) ended Thursday session in red amid volatile trading. The shares closed down -0.024 points or -3.05% at $0.776 with 280,965 shares getting traded. Post opening the session at $0.80, the shares hit an intraday low of $0.75 and an intraday high of $0.80 and the price vacillated in this range throughout the day. The company has a market cap of $12.61 million and the numbers of outstanding shares have been calculated to be 16.26 million shares.
StemCells Inc (STEM) and Microbot Medical Ltd., a private company organized under the laws of the State of Israel (“Microbot”), recently declared that they have reached a definitive merger agreement, with plans to pursue the development of robotics based medical devices for the treatment of cerebrospinal fluid and gastrointestinal disorders, in addition to other conditions.
“This transaction concludes an extensive search for planned alternatives conducted by StemCells since we failed to see robust clinical results in our Phase II clinical study of human neural stem cells in chronic spinal cord injury,” said Ian Massey, the CEO of StemCells, Inc. “We believe both our shareholders and the market at large will see the potential of Microbot’s robotics platform, specifically its catheter and shunt technologies, and will appreciate Microbot’s overall business opportunities and potential.”